MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

GlobalData estimates Keytruda to bring in over $33bn in 2028. GlobalData is the parent company of Pharmaceutical Technology. "MSD’s Keytruda sprints towards label expansion in endometrial cancer ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...

MSD and Eisai have announced mixed results from a Phase III trial of a Keytruda (pembrolizumab) combination as a first-line treatment for patients with metastatic human epidermal growth factor ...